Anglicheau D, Verstuyft C, Puig P, Becquemont L, Schlageter M, Cassinat B, Beaune P, Legendre C, Thervet E (2003). Association of the Multidrug Resistance-1 Gene Single- Nucleotide Polymorphisms with the tacrolimus dose requirements in renal transplant recipients.

J. Am. Soc. Nephrol. 14:1889-1896.

Bellusci CP, Rocco C, Aulicino P, Mecikovsky D, Curras V, Hegoburu S, Bramuglia GF, Bologna R, Sen L, Mangano A (2013). Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children. Gene 522:96-101
Crossref

Brambila-Tapia AJL (2013). MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev. Investig. Clin. 65:445-454.

Brandenberg O, Dhlamini Z, Sensi A, Ghosh K, Sonnino A (2011). Introduction to Molecular Biology and Genetic Engineering, Rome, Italy: FAO.

Brinkmann U, Eichelbaum M (2001). Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogn. J. 1:59-64.
Crossref

Buzoianu AD, Sabin O, BocÅŸan CI, Militaru C (2009). MDR1 gene polymorphism and refractory epilepsy. Ther. Pharm. Clin. Toxicol. 13:375-380.

Choudhuri S, Klaassen CD (2006). Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25:231-259.
Crossref

Cox AG (2010). Pharmacogenomics and drug transport/efflux. In: Martin M. Zdanowicz (ed.), Concepts in pharmacogenomics. Bethesda, Maryland: American Society of Health-System Pharmacists. pp. 130-153.

Dallas S, Miller D S, Bendayan R (2006). Multidrug Resistance-Associated Proteins: Expression and function in the central nervous system. Pharmacol. Rev. 58:140-161.
Crossref

Dean M, Hamon Y, Chimini G (2001). The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42:1007-1017.
Crossref

Dietrich CG, Geier A, Elferink RP (2003). ABC of oral bioavailability: transporters as gatekeepers in the gut. Recent Adv. Basic Sci. 52:1788-1795.

Eichelbaum M, Sundberg M, Evans W (2006). Pharmacogenomics and individualized drug therapy. Ann. Rev. Med. 57:119-137.
Crossref

Ekhart C, Rodenhuis S, Smits PHM, Beijnen JH, Huitema ADR (2009). An overview of the relation between polymorphisms in drug metabolizing enzymes and drug transporters and survival after cancer drug treatment. Cancer Treatment Rev. 35:18-31.
Crossref

Engman H (2003). Intestinal barriers to oral drug absorption: Cytochrome P450 3A and ABC-transport proteins Comprhensive summaries of Uppsala Dissertations from the Faculty of Pharmacy 296, Acta Universtatis Upsaliensis Uppsala Sweden. P 66.

Estudante M, Morais JG, Soveral G, Benet LZ (2013). Intestinal drug transporters: An overview. Adv. Drug Deliv. Rev. 3:1340-1356.
Crossref

Evans WE, McLeod HL (2003). Pharmacogenomics — Drug disposition, drug targets, and side effects. N Engl. J. Med. 348: 538-549.
Crossref

Franke RM, Gardner ER, Sparreboom A (2010). Pharmacogenetics of drug transporters. Curr. Pharm. Design 16:220-230.
Crossref

Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004). The Role of ABC Transporters in Drug Resistance, Metabolism, and Toxicity. Curr. Drugs 1:1-16.
Crossref

Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C (2006). MDR1 Single Nucleotide Polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res. 12:854-859.
Crossref

Higgins CF (2001). ABC transporters: physiology, structure and mechanism – an overview. Res. Microbiol. 1:205-210.
Crossref

Li J, Bluth MH (2011). Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmacogn. Person Med. 4:11-33.

Linton KJ (2007). Structure and function of ABC transporters. Am. J. Physiol. 22:122-130.
Crossref

Ma Q, Lu AYH (2011). Pharmacogenetics, pharmacogenomics and individualized medicine. Pharmacol. Rev. 63:437-459.
Crossref

Meletiadis J, Chanock S, Walsh TJ (2006). Human pharmacogenomic variations and their implications for antifungal efficacy. Clin. Microbiol. Rev. 19:763-787.
Crossref

Nakamura T, Yamamori M, Sakaeda T (2008). Pharmacogenetics of intestinal absorption. Curr. Drug Deliv. 5:153-169.
Crossref

National Health and Medical Research Council (NHMRC) (2000).Ethical Aspects of Human Genetic Testing. Australia, Commonwealth of Australia. pp. 7-57.

Novoa SR, Barreiro P, Necher IJ, Rendon A, Soriano V (2005). Pharmacogenetics in HIV therapy. AIDS Rev. 7:103-112.

Pechandova K, Buzkova H, Slanar O, Perlik F (2006). Polymorphisms of the MDR1 Gene in the Czech Population. Folia Biol. 52:184-189.

Ponnala S, Chaudhari JR, Jaleel MA, Bhiladvala D, Kaipa PR, Das UN, Hasan Q (2012). Role of MDR1 C3435T and GABRG2 C588T Gene polymorphisms in seizure occurrence and MDR1 effect on anti-epileptic drug (phenytoin) absorption. Genet. Test Mol. Biomarkers 1:1-7.

Procko E, O'Mara ML, Bennett WFD, Tieleman DP, Gaudet R (2009). The mechanism of ABC transporters: general lessons from structural and functional studies of an antigenic peptide transporter. FASEB J. 23:1287-1302.
Crossref

Regmi B, Bharati L (2012). Genetic Variation in Drug Disposition. In: Noreddin A (edr) Readings in Advanced Pharmacokinetics - Theory, Methods and Applications. Ayman Noreddin (ed.) Nepal, In Tech. pp. 101-110.
Crossref

Sailaja K, Surekha D, Rao DN, Raghunadharao D, Vishnupriya S (2010). Association of MDR1 gene polymorphism (G2677T) with chronic myeloid leukemia. Bio Med. 2:17-21.

Salama NN, Eddington ND, Fasano A (2006). Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58:15-28.
Crossref

Sankatsing SUC, Beijnen JH, Schinkel AH, Lange JMA, Prins JM (2004). P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy. J. Virol. 48:1073-1081.
Crossref

Schork NJ, Fallin D, Lanchbury S (2000). Single nucleotide polymorphisms and the future of genetic epidemiology. Clin. Genet. 58:250-264.
Crossref

Sharom FJ (2008). ABC multidrug transporters: structure, function and role in chemoresistance. J. Pharmacogn. 9:105-127.
Crossref

Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, Figg WD (2012). Transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov. Med. 13:19-34.

Solas C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, Brunet C, Gastaut JA, Durand A, Lacarelle B, Poizot-Martin I (2007). Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br. J. Clin. Pharmacol. 64:353-362.
Crossref

Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher UI, Palandra J, Gregor JC, Dresser GK, Kim RB (2008). Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogn. Genomics 18:439-448.
Crossref

Yang Z (2013). The Roles of Membrane Transporters on the Oral Drug Absorption. Mol. Pharm. Organ. Proc. Res. 1:1-4.

Zamboni WC, Ramanathan RK, McLeod HL, Mani SL, Potter DM, Strychor S, Maruca LJ, King CR, Jung LL, Parise RA, Egorin MJ, Davis TA, Marsh S (2006). Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Investig. New Drugs 24:393-401.
Crossref

Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Jiang F, Huang YF, Zhou HH (2006). Role of BCRP 421C> A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chem. Acta 373:99-103.
Crossref